Both positron emission tomography (PET) and magnetic resonance spectroscopic imaging (MRSI) can give important information about cancer metabolism. With an integrated PET/MR scanner, MRSI and PET images can be acquired simultaneously. The aim of this study was to examine possible correlations between 18F-Fluciclovine PET and MRSI measurements and evaluate their diagnostic performance in prostate cancer. The results showed a significant moderate correlation between both SUVmean and SUVmax and the CCS/C ratio. A combination of the imaging outcomes derived from the integrated PET-MRSI modalities improved the localization accuracy of prostate cancer lesions.